

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/522,900	03/10/2000	Alison A. McCormick	LSB-001	4521
7	590 12/13/2001			
VENABLE Suite 1000 1201 New York Avenue			EXAMINER	
			BANSAL, GEETHA P	
Washington, DC 20005-3917			ART UNIT	PAPER NUMBER
			1642	10
			DATE MAILED: 12/13/2001	×

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No. Applicant(s)		
	09/522900 McCormel etal		
Office Action Summary	Examiner Group Art Unit		
	Gella Bansa 1648		
—The MAILING DATE of this communication appears	on the cover sheet beneath the correspondence address—		
Peri df r Reply			
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO OF THIS COMMUNICATION.	EXPIREMONTH(S) FROM THE MAILING DATE		
from the mailing date of this communication.			
Status			
☐ Responsive to communication(s) filed on	•		
☐ This action is FINAL.			
 Since this application is in condition for allowance except f accordance with the practice under Ex parte Quayle, 1935 	or formal matters, prosecution as to the merits is closed in C.D. 1 1; 453 O.G. 213.		
Disp sition of Claims			
$\mathbb{C}(Claim(s) = 1-53$	is/are pending in the application.		
Of the above claim(s)	is/are withdrawn from consideration.		
☐ Claim(s)	is/are allowed.		
☐ Claim(s)	is/are rejected.		
□ Claim(s)	is/are objected to.		
α Claim(s) $1-53$	are subject to restriction or election requirement.		
Application Papers			
$\hfill \square$ See the attached Notice of Draftsperson's Patent Drawing			
☐ The proposed drawing correction, filed on			
☐ The drawing(s) filed on is/are objected.	d to by the Examiner.		
 The specification is objected to by the Examiner. The oath or declaration is objected to by the Examiner. 			
Pri rity under 35 U.S.C. § 119 (a)-(d)			
 □ Acknowledgment is made of a claim for foreign priority und □ All □ Some* □ None of the CERTIFIED copies of the □ received. □ received in Application No. (Series Code/Serial Number) 	e priority documents have been		
□ received in Application No. (Series Code/Serial Number			
*Certified copies not received:			
Attachment(s)			
☐ Information Disclosure Statement(s), PTO-1449, Paper No	(s) ☐ Interview Summary, PTO-413		
☐ Notice of Reference(s) Cited, PTO-892	□ Notice of Informal Patent Application, PTO-152		
☐ Notice of Draftsperson's Patent Drawing Review, PTO-948	Other PAY Transmital form		
Office	Acti n Summary		

Application/Control Number: 09/522, 900 Page 2

Art Unit: 1642

DETAILED ACTION

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-23, 29, 37-40, drawn to a tumor specific vaccine product, classified in class 424, subclass 277.1.
 - II. Claims 24-28, 30-36, drawn to a immunogenic protein specific for an in vidual, classified in class 424, subclass 184.1.
 - III. Claims 41-50, drawn to a method of inducing an immune response, classified in class 424, subclass 131.1.
 - IV. Claims 51-53, drawn to a method producing a polypeptide, classified in class 435, subclass 69.1.
- 2. The inventions are distinct, each from the other because of the following reasons: Inventions I and II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (M.P.E.P. § 806.04, M.P.E.P.. § 808.01). In the instant case, the different inventions are drawn to different structurally and chemically distinct products which have different modes of operation and have different uses. Each of the groups is capable of being used independent of the others and form patentably distinct products.

3. Inventions III-IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (M.P.E.P.. § 806.04, M.P.E.P.. § 808.01). In the instant case, the different inventions are drawn to different methods.. The Groups are drawn to methods which are distinct and independent as they require different method steps, reagents, therapeutic variables and rely on different endpoints.

Application/Control Number: 09/522, 900 Page 3

Art Unit: 1642

4. Invention drawn to products of Groups I or II and methods of Groups III or IV may be considered to be related as product and processes of use and making. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (M.P.E.P.. § 806.05(h)). In the instant case the product of the said Groups can be also used in immunoaffinity purification methods or in other biochemical studies in vitro. The process of making the invention of Group I or II can be practiced by isolation from natural sources, without the use of a recombinant technology.

- 5. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, their recognized divergent subject matter, and the search required for the different Groups are different, restriction for examination purposes as indicated is proper.
- 6. Due to the numerous groups and the complexity of the groupings this written restriction is being mailed. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- 7. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).

Art Unit: 1642

8. A dedicated Fax machine is in place to receive your responses. The Fax number is 703-308-4315. A Fax cover sheet is attached to this Office Action for your convenience. Please limit the use of this dedicated Fax number to responses to Written Restrictions.

- 9. Papers related to this application may be submitted to Group 1640 by facsimile transmission. Papers should be faxed to Group 1640 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center telephone number is (703) 308-4242 or (703) 305-3014.
- 10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Geetha P. Bansal whose telephone number is (703) 305-3955. The examiner can normally be reached on Mondays to Thursdays from 7:00am to 4:30pm and alternate Fridays from 7:00am to 3:30pm. A message may be left on the examiner's voice mail service.
- 11. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Anthony Caputa, can be reached on (703) 308-3995.
- 12. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

December 11, 2001.

GEETHA P. BANSAL PRIMARY EXAMINER

Page 4